# US 2001/0034357 A1 · Substituted pyridine compounds useful for controlling chemical synaptic transmission

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034357 A1
- Document ID: US20010034357A1
- Status: Published application
- Kind: A1
- Application number: 09/496,538
- Filed: 2000-02-02
- Published: 2001-10-25
- Earliest claimed: 2000-02-02
- Inventors: Nan-Horng Lin; Liming Dong
- Web page: https://patentgrep.com/patent/US20010034357A1

## CPC

- C07D 213/65: attached in position 3 or 5
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to a series of substituted pyridine compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions containing these compounds. Preferred compounds are 3′-(5′- and/or 6′-substituted) pyridyl ethers.

## Claims

### Claim 1

A compound of the structure
10
wherein n is an integer of 1 to 4;
R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aralkyl and cyanomethyl;
R3, at each occurrence, is selected from the group consisting of hydrogen, haloalkyl and lower alkyl;
R4, at each occurrence, is independently selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, alkenoxy, alkynoxy, thioalkoxy, aliphatic acyl, —CF3, nitro, cyano, —N(C1—C3 alkyl)-C(O)(C1—C3 alkyl), —C1—C3 alkylamino, alkenylamino, alkynylamino, di(C1—C3 alkyl)amino, amino, halogen, —C(O)O—(C1—C3 alkyl), —C(O)NH—(C1—C3 alkyl), —C(O)N(C1—C3 alkyl)2, haloalkyl, alkoxylcarbonyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, aliphatic acyl, —CH═NOH, —PO3H2, —OPO3H2, heterocyclylalkyl, cycloalkynyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, heterocyclyl, heterocycloyl, alkylaryl, aralkyl, aralkenyl, alkylheterocyclyl, sulfonyl, sulfonamido, carbamate, aryloxyalkyl, carboxyl and —C(O)NH(benzyl);
R5 is selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, lower alkylamino and lower alkoxy;
R6 is selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, alkenoxy, alkynoxy, thioalkoxy, aliphatic acyl, —CF3, nitro, amino, cyano, —N(C1—C3 alkyl)-C(O)(C1—C3 alkyl), —C1—C3 alkylamino, alkenylamino, alkynylamino, di(C1—C3 alkyl)amino, —C(O)O—(C1—C3 alkyl), —C(O)NH—(C1—C3 alkyl), —CH═NOH, —C(O)N(C1—C3 alkyl)2, haloalkyl, alkoxylcarbonyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, aliphatic acyl, —CH═NOH, —PO3H2, —OPO3H2, heterocyclylalkyl, cycloalkynyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, heterocyclyl, heterocycloyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, sulfonyl, sulfonamido, carbamate, aryloxyalkyl, carboxyl and —C(O)NH(benzyl); and
A is selected from the group consisting of —O—, —S—, —N(R1)—, —SO2N(R1)— and —NR1SO2—;
wherein R1, R2, R3, R4, R5 and R6 are unsubstituted or substituted with at least one electron donating or electron withdrawing group;
and pharmaceutically acceptable salts thereof;
with the proviso that when A═O at least one of R5 or R6 is halogen;
and with the further proviso that when R3 and R4 are attached to a carbon which is alpha to a heteroatom, R4 is not halogen, hydroxyl or amino.

### Claim 2 (depends on 1)

A compound of claim 1 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, amides and pro-drugs thereof.

### Claim 3 (depends on 1)

A compound of claim 1 of the structure
11
wherein n is an integer of 1 to 4;
R1and R2 are independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aralkyl and cyanomethyl;
R3, at each occurrence, is selected from the group consisting of hydrogen, haloalkyl and lower alkyl;
R4, at each occurrence, is independently selected from the group consisting of hydrogen, hydroxyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, alkenoxy, alkynoxy, thioalkoxy, aliphatic acyl, —CF3, nitro, cyano, —N(C1—C3 alkyl)-C(O)(C1—C3 alkyl), —C1—C3 alkylamino, alkenylamino, alkynylamino, di(C1—C3 alkyl)amino, amino, halogen, —C(O)O—(C1—C3 alkyl), —C(O)NH—(C1—C3 alkyl), aliphatic acyl, —CH═NOH, —PO3H2, —OPO3H2, heterocyclylalkyl, —C(O)N(1—C3 alkyl)2, haloalkyl, alkoxylcarbonyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, heterocyclyl, heterocycloyl, alkylaryl, aralkyl, aralkenyl, alkylheterocyclyl, sulfonyl, sulfonamido, carbamate, aryloxyalkyl, carboxyl and —C(O)NH(benzyl);
R5 is selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, lower alkylamino and lower alkoxy; and
R6 is selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, alkenoxy, alkynoxy, thioalkoxy, aliphatic acyl, —CF3, nitro, amino, cyano, —N(C1—C3 alkyl)-C(O)(C1—C3 alkyl), —C1—C3 alkylamino, alkenylamino, alkynylamino, di(C1—C3 alkyl)amino, —C(O)O—(C1—C3 alkyl), —C(O)NH—(C1—C3 alkyl), —CH═NOH, —C(O)N(C1—C3 alkyl)2, haloalkyl, alkoxylcarbonyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, aliphatic acyl, —CH═NOH, —PO3H2, —OPO3H2, heterocyclylalkyl, cycloalkynyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, heterocyclyl, heterocycloyl, alkylaryl, aralkyl, aralkenyl, alkylheterocyclyl, sulfonyl, sulfonamido, carbamate, aryloxyalkyl, carboxyl and —C(O)NH(benzyl);
wherein R1, R2, R3, R4, R5 and R6 are unsubstituted or substituted with at least one electron donating or electron withdrawing group;
and pharmaceutically acceptable salts thereof;
with the proviso that when R3 and R4 are attached to a carbon which is alpha to a heteroatom, R4 is not halogen, hydroxyl or amino,
and with further proviso that at least one of R5 or R6 is halogen.

### Claim 4 (depends on 3)

A compound of claim 3 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, amides and pro-drugs thereof.

### Claim 5 (depends on 3)

A compound of claim 3 wherein n=2, R5 is halogen and R6 is selected from the group consisting of hydrogen, lower alkyl and halogen.

### Claim 6 (depends on 1)

A compound of claim 1 of the structure
12
wherein n is an integer of 1 to 4;
R1 and R2 are independently selected from the group consisting of hydrogen and lower alkyl;
R3 is selected from the group consisting of hydrogen, haloalkyl and lower alkyl;
R5 is selected from the group consisting of hydrogen, halogen, lower alkyl, nitro, lower alkylamino and lower alkoxy; and
R6 is selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, alkenoxy, alkynoxy, thioalkoxy, aliphatic acyl, —CF3, nitro, amino, cyano, —N(C1—C3 alkyl)-CO(C1—C3 alkyl), —C1—C3 alkylamino, alkenylamino, alkynylamino, di(C1—C3 alkyl)amino, —C(O)O—(C1—C3 alkyl), —CH═NOH, —C(O)NH—(C1—C3 alkyl), —C(O)N(C1—C3 alkyl)2, haloalkyl, alkoxylcarbonyl, alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl, heterocyclyl, heterocycloyl, alkylaryl, aralkyl, aralkenyl, alkylheterocyclyl, sulfonyl, sulfonamido, carbamate, aliphatic acyl, —CH═NOH, —PO3H2, —OPO3H2, heterocyclylalkyl, aryloxyalkyl, carboxyl and —C(O)NH(benzyl);
wherein R1, R2, R3, R5 and R6 are unsubstituted or substituted with at least one electron donating or electron withdrawing group;
and pharmaceutically acceptable salts thereof;
with the proviso that at least one of R5 or R6 is halogen.

### Claim 7 (depends on 6)

A compound of claim 6 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, amides and pro-drugs thereof.

### Claim 8 (depends on 6)

The compound of claim 6 wherein R5 and R6 are each independently selected from the group consisting of lower alkyl, —F, —Cl and —Br; n is 1 and R3 is selected from the group consisting of haloalkyl and lower alkyl.

### Claim 9 (depends on 6)

The compound of claim 6 wherein R5 and R6 are each independently selected from the group consisting of lower alkyl, —F, —Cl and —Br; n is 2 and R3 is selected from the group consisting of haloalkyl and lower alkyl.

### Claim 10 (depends on 3)

The compound according to claim 3 selected from the group consisting of 5-[(S)-2-amino-1-propyloxy]-2-chloro pyridine, 5-[(S)-2-methylamino-1-propyloxy]-2-chloro pyridine, 5-[(S)-2-amino-1-propyloxy]-2-fluoro pyridine, 5-[(S)-2-methylamino-1-propyloxy]-2-fluoro pyridine, 5-[(S)-2-methylamino-1-propyloxy]-2-chloro-3-bromo pyridine, 5-[(S)-2-methylamino-1-propyloxy]-2-chloro-3-methyl pyridine and pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

A compound of claim 10 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, amides and pro-drugs thereof.

### Claim 12 (depends on 1)

A method for controlling neurotransmitter release in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising:
a compound of claim 1 and pharmaceutically acceptable salts thereof;
in a pharmaceutically acceptable carrier.
